To conclude, the work here presented provides a first proof of concept for two novel, versatile protein drugs designed to selectively target TNF and IFN‐γ activity to the tumor vasculature and which in different combination modalities can lead to eradication of large established tumors without toxicity. This evidence concerns the gene TNF and neoplasm.